Amber Therapeutics Reports Results from the AURA-2 Study of Amber-UI Pudendal Neuromodulation System for Urinary Incontinence
Shots:
- The AURA-2 study investigated the safety of Amber-UI pudendal neuromodulation system in either severe refractory urge UI or mixed UI women (n=13)
- The study confirmed the method’s safety for implanting two electrode leads on the pudendal nerve while efficacy data showed complete resolution of incontinence episodes in 4/5 evaluable women with mixed UI at 6mos.
- Furthermore, the acute stimulation effects on barrier muscle functions & detrusor overactivity suppression led to increased mean cystometric capacity & resulted in reduced stress & urge incontinence events in mixed UI patients. The study highlighted the efficacy of patient-controlled adaptive algorithms using integrated sensors to detect real-time pelvic neuromuscular activity, in vivo
Ref: Amber Therapeutics | Image: Amber Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
